Amgen Drops 7% After A 'Big, Unknown Risk' Rattles Obesity Shot

By Investor's Business Daily | Nov 12, 2024 at 04:16 PM EST

Amgen's stock fell due to concerns about MariTide's impact on bone mineral density. Analysts remain optimistic but acknowledge risks. Amgen's weight-loss shot faces competition from Novo Nordisk and Eli Lilly. Pfizer is also developing a similar drug.

Did you find this insightful?

Bad

Just Okay

Amazing

We are preparing, please wait

New Alert

Select an alert type

Sentiment Spike

Send email alert if news sentiment changes significantly

Mentions Spike

Send email alert if has a surge in mentions

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.